Liquid Biopsy-based Monitoring System for Relapse of HCC After Liver Transplantation: A Multi-center and Prospective Study

Zhejiang University

Status: Unknown

Conditions: Hepatocellular Carcinoma

Treatments: Other: Risk model of tumor relapse

Study type: Observational

Funder types: Other

Identifiers

NCT03708705

ZJUXU1177

Details and patient eligibility

About

This study aims to develop a novel, reliable, liquid biopsy-based biomarker system for relapse of HCC associated with hepatitis B after liver transplantation.

Full description

Relapse of hepatocellular carcinoma (HCC) is one of the leading causes of death after liver transplantation (LT). Detection of cancer at an earlier stage of the disease can be critical to improve patient survival. Liquid biopsy is a revolutionary technique that is opening previously unexpected perspectives. It consists of circulating extracellular vesicles, nucleic acids (DNA and RNA) and circulating tumor cells. The detection and isolation of circulating tumor cells, circulating tumor DNA and exosomes, as a source of genomic and proteomic information in patients with cancer. Regarding these promising and potential transformative tools, as well as the issues still needed to be addressed for adopting various liquid biopsy approaches into clinical practice. This study aims to develop a novel, reliable, liquid biopsy-based biomarker system for relapse of HCC associated with hepatitis B after liver transplantation.

Enrollment: 500 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

transplants for HCC

Exclusion criteria

Liver transplantation due to other disease

Trial design

500 participants in 2 patient groups

Relapse

Description:

Relapse of tumor within two years after liver transplantation

Treatment:

Other: Risk model of tumor relapse

Non-relapse

Description:

Non-relapse of tumor within two years after liver transplantation

Treatment:

Other: Risk model of tumor relapse